<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150862</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-104</org_study_id>
    <secondary_id>2017-001554-33</secondary_id>
    <nct_id>NCT03150862</nct_id>
  </id_info>
  <brief_title>A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma</brief_title>
  <official_title>A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, efficacy and clinical activity of Pamiparib in
      combination with radiation therapy (RT) and/or temozolomide (TMZ) in subjects with newly
      diagnosed or recurrent/refractory glioblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open‑label, multiple‑dose, dose-escalation study to determine the safety, pharmacokinetics
      (PK) and pharmacodynamics (PD) of Pamiparib in combination with radiation therapy (RT) and/or
      TMZ.

      In dose escalation/Phase 1b, Pamiparib will be combined with RT (Arm A) or RT and TMZ (Arm B)
      in subjects with newly diagnosed unmethylated glioblastoma (GBM) and in Arm C of the study
      Pamiparib will be combined with TMZ in subjects with methylated or unmethylated
      recurrent/refractory GBM.

      The dose expansion/Phase 2 phase will enroll up to 4 cohorts: subjects with newly diagnosed
      unmethylated GBM in Arms A and B, and 2 cohorts of subjects with recurrent/refractory GBM
      grouped by MGMT status - unmethylated or methylated - in Arm C.

      Subjects in Arms A and B are treated until completion of RT and subjects in Arm C may
      continue treatment in the absence of safety concerns and disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No Masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE</measure>
    <time_frame>From first dose Pamiparib to 10 weeks post-dose (Arms A and B). From first dose Pamiparib to 28 days post-dose (Arm C).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE</measure>
    <time_frame>From first dose Pamiparib to 30 days post final dose of pamiparib +/- RT or TMZ.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment</measure>
    <time_frame>From first dose Pamiparib to 30 days post final dose of pamiparib +/- RT or TMZ.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Arm A [Pamiparib + RT] and Arm B [Pamiparib + RT + TMZ]: Modified disease control rate (mDCR) using mRANO</measure>
    <time_frame>From first dose Pamiparib to first documentation of progression while subject is alive, assessed up to 5 years.</time_frame>
    <description>Modified disease control rate (DCR) using mRANO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Arm C [Pamiparib + TMZ]: Objective response rate (ORR) using mRANO</measure>
    <time_frame>From first dose of Pamiparib to first documentation of progression assessed up to 5 years.</time_frame>
    <description>Objective response rate (ORR) using mRANO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of Pamiparib of steady state Ctrough</measure>
    <time_frame>From first dose Pamiparib to 30 days post-final dose of pamiparib +/- RT or TMZ.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified disease control rate (DCR). (Arms A and B)</measure>
    <time_frame>From first dose Pamiparib to first documentation of disease progression while subject is alive assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (Arm C)</measure>
    <time_frame>From first dose Pamiparib to first documentation of disease progression while subject is alive assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From first dose Pamiparib to first documentation of disease progression while subject is alive assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR).</measure>
    <time_frame>From first dose Pamiparib to first documentation of disease progression while subject is alive assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR).</measure>
    <time_frame>From first dose Pamiparib to first documentation of progression while subject is alive, assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS).</measure>
    <time_frame>From first dose Pamiparib to first documentation of progression while subject is alive, assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose Pamiparib until date of death, assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR).</measure>
    <time_frame>From the first dose Pamiparib to first documentation of disease progression, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>From first dose Pamiparib to first documentation of disease progression, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From first dose Pamiparib to first documentation of disease progression, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose Pamiparib to first documentation of disease progression, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose Pamiparib + RT +/- TMZ until date of death, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE</measure>
    <time_frame>From first dose Pamiparib + RT +/- TMZ to 30 days post- last dose of pamiparib or RT whichever is later</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of treatment, dose intensity of components of each treatment , and changes in vital signs and clinical laboratory tests during and following treatment</measure>
    <time_frame>From first dose Pamiparib + RT +/- TMZ to 30 days post- last dose of pamiparib or RT whichever is later</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of Pamiparib of steady state Ctrough</measure>
    <time_frame>From first dose Pamiparib to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of Pamiparib (Cmax)</measure>
    <time_frame>From first dose Pamiparib to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR).</measure>
    <time_frame>From first dose Pamiparib + RT +/- TMZ to first documentation of progression while subject is alive, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR).</measure>
    <time_frame>From first dose of Pamiparib to first documentation of disease progression, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose of Pamiparib to first documentation of disease progression or death, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose Pamiparib until date of death, assessed up to 5 years.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE</measure>
    <time_frame>From first dose Pamiparib + TMZ to 30 days post last dose Pamiparib or TMZ, whichever is later).</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment</measure>
    <time_frame>From first dose Pamiparib + TMZ to 30 days post last dose Pamiparib or TMZ (whichever is later).</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of Pamiparib of steady state Ctrough</measure>
    <time_frame>From first dose Pamiparib to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of Pamiparib (Cmax)</measure>
    <time_frame>From first dose Pamiparib to 30 days post-dose.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Dose Expansion-Cohorts C1 and C2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <description>BGB-290</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm A (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm C (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm C (Dose Expansion-Cohorts C1 and C2)</arm_group_label>
    <other_name>Pamiparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ</intervention_name>
    <description>TMZ</description>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm C (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm C (Dose Expansion-Cohorts C1 and C2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Up to 60 Gy (total) over 6 - 7 weeks</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm A (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All subjects

          1. Age ≥ 18 years old.

          2. Confirmed diagnosis of glioblastoma (WHO Grade IV).

          3. Agreement to provide archival tumor tissue for exploratory biomarker analysis

          4. Ability to undergo serial MRIs.

          5. ECOG status ≤ 1.

          6. Adequate hematologic and end-organ function

          7. Females of childbearing potential and non-sterile males must agree to use highly
             effective methods of birth control throughout the course of study and at least up to 6
             months after last dosing.

          8. Ability to swallow whole capsules.

             Subjects in Arms A and B (not Arm C) must meet inclusion criteria # 9 - 11:

          9. No previous treatment for GBM except surgery.

         10. Able to start radiation therapy ≤ 49 days after surgery but ≥ 14 days after a biopsy
             or ≥28 days after an open biopsy or craniotomy with adequate wound healing.

         11. Documented unmethylated MGMT promoter status.

             Subjects in Arm C Escalation (Phase 1b) must meet inclusion criteria # 12 - 15:

         12. Documentation of MGMT promoter status

         13. No prior systemic chemotherapy other than TMZ for GBM.

         14. Histologically confirmed secondary glioblastoma

         15. Disease that is evaluable or measurable as defined by RANO criteria

             Subjects in Arm C Expansion (Phase 2), must meet criteria # 16 - 18:

         16. Histologically confirmed de novo (primary) glioblastoma with unequivocal first
             progressive disease (PD) after RT with concurrent/adjuvant TMZ chemotherapy

         17. Disease that is measurable as defined by RANO criteria

         18. Documentation of MGMT promoter status

        Exclusion Criteria: All subjects

          1. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents ≤21 days
             prior to start of study treatment.

          2. Toxicity of ≥ Grade 2 from prior therapy.

          3. Major surgery or significant other injury ≤ 4 weeks prior to start of study treatment.

          4. History of other active malignancies within 2 years with exception of (i) adequately
             treated in situ cancer of the cervix, (ii) non-melanoma skin cancer, or (iii)
             localized adequately treated cancer with curative intent or malignancy diagnosed &gt; 2
             years ago with no evidence of disease and no treatment ≤ 2 years prior to study
             treatment.

          5. Active infection requiring systemic treatment.

          6. Known human immunodeficiency virus (HIV) or active viral hepatitis.

          7. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease,
             ventricular arrhythmia or CVA ≤ 6 months prior to start of treatment.

          8. Active clinically significant gastrointestinal disease.

          9. Active bleeding disorder ≤ 6 months prior to start of treatment.

         10. Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants.

         11. Use of any medications or food known to be strong or moderate cytochrome P450, family
             3, subfamily A (CYP3A) inhibitors or strong inducers.

         12. Pregnant or nursing females.

         13. Significant intercurrent illness that may result in subject's death prior to death
             from glioblastoma.

             Arms B and C Only:

         14. Known hypersensitivity to any component of TMZ or decarbazine (DTIC).

         15. Have hereditary problems of galactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Wood, RN</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Neuro-Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Health One</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Pappas Center for Neuro-Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Midwest Ventures Group, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center (Stephenson Cancer Center)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI / Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94850</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zuerich - Klinik fur Neurologie</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult glioblastoma, adult gian cell glioblastoma, adult gliosarcoma, glioma neoplasms</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>neoplasms, central nervous system neoplasms, neoplasms by histologic type, neoplasms by site</keyword>
  <keyword>astrocytoma</keyword>
  <keyword>neuroepithelial</keyword>
  <keyword>neuroectodermal tumors</keyword>
  <keyword>germ cell and embryonal</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>glandular and epithelial</keyword>
  <keyword>nerve tissue, nervous system diseases</keyword>
  <keyword>temozolomide</keyword>
  <keyword>BGB-290</keyword>
  <keyword>alkylating, alkylating agents</keyword>
  <keyword>molecular mechanisms of pharmacological action</keyword>
  <keyword>Poly(ADP-ribose) polymerase inhibitors</keyword>
  <keyword>enzyme inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

